Objectives: We previously reported inferior outcomes for locally advanced head and neck
cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this …

Objective: Whether or not cisplatin and cetuximab are similarly effective in improving
outcomes when added to radiation therapy (RT) in squamous cell carcinoma of the head …

Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

Background The addition of cisplatin or cetuximab to radiation therapy (RT) improves
outcomes in comparison with RT alone in the nonoperative management of head and neck …

Background The purpose of this study was to present our experience utilizing cetuximab and
platinum‐based concurrent chemoradiotherapy for the definitive treatment of head and neck …

Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …

PURPOSE We performed an open-label randomized controlled phase III study comparing
treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus …

Purpose We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal
growth factor receptor (EGFR), into the induction therapy and subsequent …

Purpose We report a subgroup analysis primarily focused on human papillomavirus (HPV)-
related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus …

Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …